BofA IG Healthcare Weekly: Vital Signs

Research evidence excerpt

BofA IG Healthcare Weekly: Vital Signs

Accessible version

BofA IG Healthcare Weekly

Vital Signs

Industry Overview

Healthcare Highlights: LLY, HUM, NOVNSW, VSPOPT, 11 May 2026

VTRS, BDX, ROSW High Grade Credit

United StatesThe sector priced $13.5 billion of debt with Eli Lilly ($9.0 billion), Novartis (€1.7 billion), Healthcare

Humana ($1.5 billion), and VSP Optical Group ($1.0 billion) tapping the market. Eli Lilly

issued $750 million FRNs due 2028, $750 million 4.150% notes due 2029, $500 million Andrew Kaplan

FRNs due 2029, $1.50 billion 4.375% notes due 2031, $1.25 billion 4.650% notes due ResearchBofAS Analyst

2033, $1.500 billion 4.850% notes due 2036, $1.75 billion 5.600% notes due 2056, and +1 646 855 8748

andrew.kaplan@bofa.com

$1.00 billion 5.700% notes due 2066. Novartis issued €600 million 3.100% notes due

2032, €600 million 3.500% notes due 2035, and €500 million 4.000% notes due 2041. VritikaResearchPatniAnalyst

Humana issued $750 million 6.062% notes due 2036 and $750 million 6.887% notes due BofAS

+1 646 855 7042

2056. VSP Optical Group issued $500 million 5.400% notes due 2033 and $500 million vritika.patni@bofa.com

5.650% notes due 2036. Viatris announced that Doretta Mistras, Chief Financial Officer,

will depart the company for a new professional opportunity. Viatris has named Paul

Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief

Financial Officer, effective May 8, 2026. Becton Dickinson announced that Vitor Roque has

Stock symbols and abbreviations

been named Chief Financial Officer, effective May 7. Roque has served as interim Chief BDX Becton Dickinson

Financial Officer since December 2025 and was most recently Senior Vice President, FRN Floating Rate Note

Finance and Corporate Financial Planning and Analysis.